Citizens upgrades Rocket Lab stock rating on launch capabilities

Citizens upgraded Rocket Lab (RKLB) to Market Outperform from Market Perform with an $85 price target; the stock is down ~3.0% YTD versus the S&P Aerospace & Defense ETF up 8.4%. Germany approved Rocket Lab’s ~$75M acquisition of Mynaric AG (expected close in April), prompting Cantor Fitzgerald to reiterate Overweight and Stifel to maintain a $90 target. Sector tailwinds include a proposed FY27 Department of War budget of $1.5T with ~$88.5B in space funding (including $71B for Space Force, a 78% increase) plus SpaceX IPO speculation (> $75B) and NASA’s crewed lunar mission; InvestingPro flags RKLB as overvalued on fair-value metrics.

Analysis

Rocket Lab sits at the intersection of three asymmetric forces: accelerating defense cash flows (large proposed Space Force increases), a near-term corporate M&A catalyst (Mynaric integration), and looming sector-level information flow from a SpaceX IPO. The cleanest, non-obvious beneficiary of the defense budget lift is not just launch cadence but higher-margin optical comms and hosted payload services — areas where Rocket Lab can push revenue mix toward recurring, defense-backed service contracts that lift gross margins 300–500bps versus pure vehicle sales over 12–24 months.

Countervailing risks are concrete and time-staggered. Integration execution and supply chain scaling for laser terminals (laser diodes, pointing gimbals, qualification cycles) create a 6–18 month operational risk window that can double integration costs if hit; separately, a SpaceX IPO within 6–12 months could either re-rate smaller vendors (positive) or compress valuations if SpaceX’s margins and unit economics undercut incumbent TAM assumptions. Geopolitical tail risks (regional conflict escalation) raise short-term contract wins but also increase market-wide volatility that can temporarily depress small-cap valuations by 20–35%.

The current setup favors idiosyncratic, event-driven exposure with hedges. Capture the Mynaric-close re-rating and FY27 budget read-throughs while protecting against an adverse SpaceX valuation shock or integration missteps. The highest expected payoff is from structures that limit downside to defined premium while allowing for 2.5x+ upside if defense/service contracts materialize and investor sentiment rotates back into small-cap space names over 6–12 months.

Key Decisions for Investors

• Directional, defined-risk: Buy a 9–12 month RKLB call spread (buy ATM, sell ~30% OTM) sized to 1–2% portfolio. Rationale: captures re-rating on Mynaric close and FY27 defense clarity; target 2.5x payoff if RKLB rises 40–60% in 12 months. Max loss = premium paid; unwind if spread >50% gain or RKLB falls >25% from entry.
• Event pair hedge: Long RKLB (10% allocation of the trade) / Short equal-dollar XAR (or defense large-cap ETF) to isolate idiosyncratic upside from launch/services. Hold 6–12 months; place stop-loss if RKLB underperforms XAR by 15% to limit execution/integration downside.
• Tail insurance: Buy 3–6 month RKLB put spread (10–20% OTM) financed by selling nearer-term calls to reduce cost. Purpose: protect against a negative repricing if SpaceX IPO reveals scale that compresses smaller launcher multiples. Cost ~modest premium; keeps upside participation via sold calls limited.
• Short-term catalyst trade: Enter a small call position ahead of the expected Mynaric close in April (3–4 month calls) and trim into any >20% gap up post-close. If the acquisition closes cleanly and initial contract traction is announced, take profits; cut losses if integration red flags (supplier delays, failed deliverables) are reported.